Development of effective therapeutic programmes that are useful during the early phase of HIV-1 (human immunodeficiency virus type-1) infection is a critical goal. Indeed, many patients remain asymptomatic for years before the development of clinical manifestations. Neurotropin, a well-characterized immune modulator, is known to inhibit HIV production in vitro. To further understand the relationship between effects of Neurotropin and cytopathic effects of HIV-1, the authors investigated Neurotropin-responsive molecules expressed on the HIV-infected T-cell line (MT-2) and the effect of Neurotropin on HIV-induced syncytium formation. The protein extracts from HIV-infected MT-2 cells treated with or without Neurotropin were analysed by two-dimensional polyacrylamide gel electrophoresis (2-D PAGE). Four protein molecules, designated as HMP (HIV-induced MT-2 Protein) 1, 2, 3 and 4 which were not HIV components but cellular products were derived from infected MT-2 cells. The isoelectric point of HMP-1 changed from 5.8 to 5.6 upon Neurotropin treatment. The isoelectric point of HMP-2, HMP-3 and HMP-4 did not change after Neurotropin treatment. When MT-2 cells were pretreated with 10 to 100 μg/ml of Neurotropin, HIV-induced syncytium formation was inhibited by 70% as compared to those of untreated MT-2 cells. These results suggest that HMP-1 inhibited syncytium formation by HIV-1 infected MT-2 cells may be a target of the bioactive effect of Neurotropin.
|Original language||English (US)|
|Number of pages||8|
|Journal||International Journal of Immunotherapy|
|State||Published - 1995|
ASJC Scopus subject areas
- Immunology and Allergy